Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 362
Out of 5,072 analysts
83
Total ratings
54.24%
Success rate
18.18%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $40.53 | +35.70% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $25.03 | +39.83% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $11.82 | +111.51% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $28.00 | +42.86% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $68.15 | +17.39% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $6.39 | +87.79% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $18.63 | -3.38% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $17.82 | +90.80% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $44.49 | +23.62% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $25.01 | +27.95% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $151.58 | +22.05% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $71.72 | -30.28% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $25.52 | +95.92% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $102.70 | +21.71% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $55.52 | +89.12% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $784.61 | +49.76% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $73.25 | +16.04% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $33.76 | +160.66% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $181.94 | +51.70% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.02 | +770.65% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $344.57 | -32.67% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $105.65 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $127.51 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.72 | -29.34% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.05 | +355.45% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $11.44 | +2,085.31% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.43 | +599.30% | 1 | Feb 14, 2018 |
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $40.53
Upside: +35.70%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $25.03
Upside: +39.83%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $11.82
Upside: +111.51%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $28.00
Upside: +42.86%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $68.15
Upside: +17.39%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $6.39
Upside: +87.79%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $18.63
Upside: -3.38%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $17.82
Upside: +90.80%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $44.49
Upside: +23.62%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $25.01
Upside: +27.95%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $151.58
Upside: +22.05%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $71.72
Upside: -30.28%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $25.52
Upside: +95.92%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $102.70
Upside: +21.71%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $55.52
Upside: +89.12%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $784.61
Upside: +49.76%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $73.25
Upside: +16.04%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $33.76
Upside: +160.66%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $181.94
Upside: +51.70%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.02
Upside: +770.65%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $344.57
Upside: -32.67%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $105.65
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $127.51
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.72
Upside: -29.34%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.05
Upside: +355.45%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $11.44
Upside: +2,085.31%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.43
Upside: +599.30%